Wave Life Sciences (WVE) Earnings Analysis
Wave Life Sciences (WVE) next reports earnings on 2026-07-30, consensus EPS -0.31 USD. Last quarter (2026-02-26) it missed with EPS -0.3 USD vs -0.28 USD est (-7.1%). It has beaten estimates in 1/5 recent quarters (20%). Trailing P/E -5.42.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does WVE next report earnings?
| Next earnings date | 2026-07-30 |
|---|---|
| Consensus EPS estimate | -0.31 USD |
| Revenue estimate | 0.01B |
WVE earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-02-26 | -0.3 USD | -0.28 USD | -7.1% | Miss |
| 2025-11-10 | -0.32 USD | -0.3 USD | -6.7% | Miss |
| 2025-05-08 | -0.29 USD | -0.27 USD | -7.4% | Miss |
| 2025-03-04 | 0.17 USD | -0.17 USD | +200% | Beat |
| 2024-08-08 | -0.25 USD | -0.21 USD | -19% | Miss |
Beat rate: 1/5 (20%) over reported quarters with consensus data.
WVE valuation and analyst view
| Trailing P/E | -5.42 |
|---|---|
| Trailing EPS | -0.91717 USD |
| Price / book | 2.25 |
| Dividend yield | 0.00% |
| Market cap | 1.09B |
| Analyst consensus | Buy (24 buy / 1 hold / 0 sell) |
| Avg price target | 13.75 USD |
Related research pages
Frequently asked questions
When is Wave Life Sciences (WVE)'s next earnings date?
Wave Life Sciences is next scheduled to report on 2026-07-30, with a consensus EPS estimate of -0.31 USD and revenue estimate of 0.01B.
Did WVE beat earnings last quarter?
In its 2026-02-26 report, WVE posted EPS of -0.3 USD versus a -0.28 USD estimate — a miss of 7.1%.
What is WVE's earnings track record?
Over the last 5 reported quarters with consensus data, WVE beat estimates 1 times (20%).
What is WVE's current P/E ratio and EPS?
WVE trades at a trailing P/E of -5.42 on trailing EPS of -0.9171651819903224 USD.
What do analysts rate WVE?
Analyst consensus is "Buy" across 25 ratings (1 strong buy, 23 buy, 1 hold, 0 sell, 0 strong sell). Average 12-month price target: 13.75 USD.